Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing Immunome develops antibody therapeutics for cancer and infectious diseases, reporting a market cap above $2 billion in the latest filing.
Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing Liquidia develops inhaled and injectable therapies for pulmonary arterial hypertension, targeting unmet needs in the U.S. biopharma market.
Private Equity-Style Fund Buys $15.7 Million in Harrow Stock as Revenue Jumps 45% Harrow’s accelerating revenue and expanding product portfolio may help explain why a fundamentals-focused investment firm just made it a new position.
These stocks are moving in today's after hours session After the conclusion of the US market's regular session on Monday, let's examine the after-hours session and unveil the notable performers among the top gainers and losers.
Could Harrow's New Sedation Pill Change Millions Of Medical Procedures Forever? Harrow, Inc. (
NASDAQ: HROW ), a U.S.-based provider of ophthalmic disease management solutions, announced on Friday that it has agreed to acquire Melt
HARROW INC (NASDAQ:HROW) Presents High Growth Momentum and Technical Breakout Opportunity Harrow Inc (HROW) is a high-growth ophthalmic pharma stock with strong revenue expansion and a bullish technical breakout setup, signaling potential upward momentum.
William Blair Bullish On Harrow's High-Margin Branded Eye Drug Strategy Harrow licensed U.S. rights to FDA-approved BYQLOVI for post-surgical eye pain and adds momentum to its branded ophthalmic drug strategy.
Jim Cramer Is 'OK' With Harrow, Recommends Buying This Energy Stock Jim Cramer takes a look at Harrow, Pfizer, Kinsale Capital, Manulife Financial, Iron Mountain and more on "Mad Money."
